Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.19 is 261% above its 5-year average of -0.12, near the high end of its 5-year range (-0.40–0.22).
15.15% above its 12-month average of 0.17.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:04:10.706Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.19
EARNINGS PER SHARE (EPS) AVG TTM
0.17
EARNINGS PER SHARE (EPS) AVG 3Y
0.00
EARNINGS PER SHARE (EPS) AVG 5Y
-0.12
EARNINGS PER SHARE (EPS) AVG 10Y
-0.21
EARNINGS PER SHARE (EPS) AVG 15Y
-0.22
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+15.15%
CURRENT VS 3Y AVG
+3700.00%
CURRENT VS 5Y AVG
+260.56%
CURRENT VS 10Y AVG
+191.04%
CURRENT VS 15Y AVG
+188.23%
CURRENT VS 20Y AVG
N/A
Niagen Bioscience Inc
Market Cap
$214.24M
Earnings Per Share (EPS)
0.19
TTM Avg
0.17
3Y Avg
0.00
5Y Avg
-0.12
Market Cap
$214.44M
Earnings Per Share (EPS)
-11.77
TTM Avg
-8.68
3Y Avg
-4.76
5Y Avg
-3.49
Market Cap
$214.64M
Earnings Per Share (EPS)
0.38
TTM Avg
0.11
3Y Avg
-0.10
5Y Avg
-0.19
Market Cap
$215.94M
Earnings Per Share (EPS)
N/A
TTM Avg
0.11
3Y Avg
0.08
5Y Avg
0.07
Market Cap
$214.35M
Earnings Per Share (EPS)
-0.79
TTM Avg
-1.48
3Y Avg
-1.81
5Y Avg
-1.82
Market Cap
$217.61M
Earnings Per Share (EPS)
-1.10
TTM Avg
-1.31
3Y Avg
-1.45
5Y Avg
-1.45
Market Cap
$207.87M
Earnings Per Share (EPS)
-5.84
TTM Avg
-4.15
3Y Avg
-12.68
5Y Avg
-12.98
Market Cap
$207.34M
Earnings Per Share (EPS)
4.12
TTM Avg
3.49
3Y Avg
2.39
5Y Avg
2.00
Market Cap
$223.55M
Earnings Per Share (EPS)
-3.22
TTM Avg
-1.33
3Y Avg
-3.00
5Y Avg
-2.91
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $214.24M | 0.19 | 0.17 | 0.00 | -0.12 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.44M | -11.77 | -8.68 | -4.76 | -3.49 |
| Compugen Ltd. (CGEN)vs › | $214.64M | 0.38 | 0.11 | -0.10 | -0.19 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.94M | N/A | 0.11 | 0.08 | 0.07 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | -0.79 | -1.48 | -1.81 | -1.82 |
| Alector, Inc. (ALEC)vs › | $217.61M | -1.10 | -1.31 | -1.45 | -1.45 |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.87M | -5.84 | -4.15 | -12.68 | -12.98 |
| Pro-Dex, Inc. (PDEX)vs › | $207.34M | 4.12 | 3.49 | 2.39 | 2.00 |
| Keros Therapeutics, Inc. (KROS)vs › | $223.55M | -3.22 | -1.33 | -3.00 | -2.91 |
| Electra Therapeutics Inc. (ETRA)vs › | $203.11M | N/A | N/A | N/A | N/A |
Trailing EPS (TTM)
$0.19
Forward EPS (Est.)
$0.14
P/E Ratio
14.4
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.22 |
| 2024-12-31 | 0.11 |
| 2023-12-31 | -0.07 |
| 2022-12-31 | -0.24 |
| 2021-12-31 | -0.40 |
| 2020-12-31 | -0.33 |
| 2019-12-31 | -0.56 |
| 2018-12-31 | -0.61 |
| 2017-12-31 | -0.26 |
| 2016-12-31 | -0.08 |
| 2015-12-31 | -0.08 |
| 2014-12-31 | -0.15 |
| 2013-12-31 | -0.13 |
| 2012-12-31 | -0.39 |
| 2011-12-31 | -0.35 |
| 2010-12-31 | -0.13 |
| 2009-12-31 | -0.09 |
| 2008-12-31 | -0.22 |
| 2007-12-31 | -0.01 |
